Your Messages Inbox
Your Article Summary
See Latest ArticlesOnce-yearly Aclasta approved in EU to treat osteoporosis caused by steroid treatment in men and postmenopausal women
Novartis, 06/29/09
Once-yearly Aclasta has been approved in the European Union to treat men and postmenopausal women with osteoporosis caused by long-term use of glucocorticoids, commonly known as steroids. Glucocorticoids are widely used to treat inflammatory conditions such as asthma and rheumatoid arthritis, but also cause bone loss and can increase the risk of fracture in up to 50% of patients on long-term glucocorticoid therapy.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
Novartis, 11/30/09
Major European regulatory milestone in cardiovascular protection for Micardis : Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients
Boehringer Ingelheim, 11/30/09
Human genome sciences submits biologics license application to fda for zalbin
Human Genome Sciences, 11/30/09
Article Search
Sponsor